Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
JCAR017 comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (J Clin Oncol 35, 2017 (suppl; abstr 7513)).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JCAR017||Lisocabtagene maraleucel|JCAR 017||JCAR017 (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (J Clin Oncol 35, 2017 (suppl; abstr 7513)).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||diffuse large B-cell lymphoma||not applicable||JCAR017||Clinical Study||Actionable||In a clinical case study, treatment with JCAR017 resulted in complete remission and durable central nervous system response in a patient with diffuse large B-cell lymphoma (PMID: 28834486).||28834486|
|Unknown unknown||B-cell lymphoma||not applicable||JCAR017||Phase I||Actionable||In a Phase I trial, JCAR017 treatment resulted in a response rate of 80% (22/28) with a complete response rate of 60% (17/28) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (J Clin Oncol 35, 2017 (suppl; abstr 7513); NCT02631044).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03483103||Phase II||JCAR017||Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)||Recruiting|
|NCT03744676||Phase II||JCAR017||A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Ldymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)||Recruiting|
|NCT04245839||Phase II||JCAR017 Cyclophosphamide + Fludarabine||A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)||Recruiting|
|NCT03331198||Phase Ib/II||JCAR017 Ibrutinib + JCAR017||Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||Recruiting|
|NCT02631044||Phase I||JCAR017||Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)||Recruiting|